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Abstract
Background: Data regarding the impact of different lipid measures on cardiovascular diseases (CVD) and mortality
events is not consistent. We aimed to evaluate the relationship between different lipid parameters and incident
CVD and mortality events in an Iranian population over a median follow-up of 11.9 years.
Methods: The study was conducted on 2532 men and 2986 women aged ≥ 40 years. Multivariate adjusted hazard
ratios (HRs), using age as time scale, were calculated for every 1 standard deviation (SD) increase in total cholesterol
(TC), logarithm-transformed triglycerides (ln-TGs), low density lipoprotein-cholesterol (LDL-C), high density
lipoprotein-cholesterol (HDL-C), non-HDL-C, TC/HDL-C and ln-TGs/HDL-C. Covariates included gender (female as
reference), body mass index, education status, low physical activity, smoking, blood pressure status (normotension,
prehypertension and hypertension), glucose tolerance status (normal glucose tolerance, prediabetes and diabetes)
and lipid lowering drugs. The same analyses were also repeated for tertiles of all lipid measures. Considering the
absence of interaction between gender and lipid parameters, we used a sex-adjusted analysis. For analyses of
mortality events, prevalent CVD was adjusted as well (All p for interactions > 0.1).
Results: A total of 789 new CVD events, 279 cardiovascular (CV) and 270 non-CV deaths occurred. In multivariate
analysis, all lipid measures except HDL-C showed significant risk for new CVD events with HRs ranged from 1.14 to
1.27 for ln-TGs/HDL-C and LDL-C, respectively (all p-values ≤ 0.001). Considering CV mortality, there were significant
positive associations between TC, LDL-C, non-HDL-C, TC/HDL-C and CV mortality events in sex-adjusted analysis;
however after multivariate analysis, these associations attenuated and reached to null. Applying lipid measures
as categorical variables, only TC displayed a positive association with CV mortality in multivariate analysis
[TC ≥ 6.14 mmol/L: HR 1.43 (1.04–1.98)].
In multivariate analysis, there were negative significant associations between all lipid measures except HDL-C and
non-CV mortality; every 1-SD increase in TC, LDL-C, non-HDL-C, ln-TGs ,TC/HDL-C and ln-TGs/HDL-C was associated
with 24, 25, 27, 19, 23 and 17 % decreased risk in non-CV mortality (all p-values ≤ 0.01).
Conclusions: These findings indicate divergent associations of TC, LDL-C, non-HDL-C, TC/HDL-C, TGs and
TGs/HDL-C with CVD vs non-CV mortality, demonstrating a higher risk for the former and lower risk for the latter.
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Background
Cardiovascular disease (CVD) is the leading cause of
30 % of mortality worldwide [1] and up to 50 % of
deaths in Iran [2]. The association between different
lipid measures and cardiovascular disease and mortality
have been shown in several studies [3–5]. Based on the
results of observational and interventional studies con-
ducted in middle-aged populations, there is a continuous
graded relationship between serum total cholesterol
(TC) levels with CVD and mortality [6]. Meanwhile,
non-high density lipoprotein cholesterol (non-HDL-C)
as the masses of cholesterol in the atherogenic apo B
lipoprotein particles has been known as a valuable pre-
dictor for cardiovascular risk [3]. In a cohort of Western
population, triglycerides (TGs) and the TC to HDL-C ra-
tio (TC/HDL-C) were more strongly associated with risk
of future coronary heart disease (CHD) [7]. Moreover, a
recent meta-analysis showed significant association be-
tween serum triglycerides (TGs) and CVD and all-cause
mortality [5]. There are several studies regarding inverse
relationship between HDL-C levels and CVD [8]. Fur-
thermore, many studies have shown that indices such as
TGs to HDL-C ratio (TG/HDL-C) and TC/HDL-C can
also predict CVD and CHD mortality [4, 9–11]. Despite
these, data regarding association between lipid measures
and mortality is not consistent [12, 13] and to the best
of our knowledge, few studies have examined this rela-
tionship considering cardiovascular (CV) vs non-CV
mortality, separately.
Almost all previous surveys regarding the association
between lipid measures and CVD or all-cause mortality
events have been performed on European, American or
the Far East populations [14, 15] and it is not clear
whether their results can be extrapolated to Middle-
Eastern population who have high incidence of CHD
and mortality events [16, 17]. Recently, a multivariate
sex-adjusted analysis showed that among Iranian adults
aged ≥ 50 years, serum levels of TC, TGs, low density
lipoprotein-cholesterol (LDL-C), non-HDL-C, and TC/
HDL-C were significantly associated with higher risk of
incident CHD, whereas HDL-C was associated with a
lower risk [18].
In the current population-based study, we expand our
previous findings and investigate the association between
seven lipoprotein measures and CVD events, CV and
non-CV mortality in more than a decade follow-up.
Methods
Study population
Subjects for the current study were selected from partic-
ipants of the Tehran Lipid and Glucose Study (TLGS), a
long term prospective population-based study being
conducted on a representative sample of Tehranian resi-
dents to determine the prevalence and incidence of non-
communicable diseases and related risk factors. Details
of TLGS have been published previously [19]. TLGS has
two main phases: a cross-sectional phase (1999–2001)
and a prospective ongoing phase consisting of follow-up
visits at 3-year intervals.
A total of 6445 individuals, aged ≥ 40 years were en-
rolled in the first (n = 5406) or second (n = 1039) phases.
To evaluate the effects of lipid markers on CVD and
non-CV mortality, after excluding participants without
any follow-up (n = 618) or with missing data for baseline
covariates (n = 309), 5518 participants with complete
data were followed for a median of 11.9 years (interquar-
tile range: 7.8–13.1 years) up to March 2012. For investi-
gating the effects of lipid measures on CVD events, the
analysis was done in a smaller sample (n = 5054) by ex-
cluding individuals with prevalent CVD.
During the third phase of the TLGS (2006–2008), a total
of 4920 participants were randomly selected for complet-
ing the dietary assessment based on their age and sex. Fi-
nally, the dietary data for 3462 subjects were completed
using a validated 168-item food frequency questionnaire
[20]. For the present study, after exclusion of participants
aged < 40 years and those with under- or over-reporting of
dietary energy intakes (<800 or ≥ 4200 kilocalories/day),
dietary information of 915 participants was included in a
sensitivity analysis. Furthermore, data regarding serum in-
sulin was available for 1548 participants at baseline which
was considered in a subgroup analysis.
The ethics committee of the Research Institute for
Endocrine Sciences, Shahid Beheshti University of Med-
ical Sciences approved the design of TLGS and all partici-
pants provided written informed consent.
Data collection
Medical history, clinical examination and laboratory
measurements
Participants were interviewed face to face by trained in-
terviewers. A standard questionnaire was used to collect
demographic information, including their smoking status
and taking of any antidiabetic or hypertension drugs.
Systolic blood pressure (SBP) and diastolic blood pres-
sure (DBP) were measured twice in a seating position on
the right arm, using a standard mercury sphygmoman-
ometer and the mean value was considered as the sub-
ject’s SBP and DBP.
Weight was measured with individuals minimally
clothed without shoes, using digital scales (Seca 707:
range 0.1–150 kg) and recorded to the nearest 0.1 kg.
Height was measured in a standing position without
shoes, using a tape meter, while shoulders were in a nor-
mal alignment. Body mass index (BMI) was calculated as
weight in kilograms divided by height in square meters.
Waist circumference (WC) was measured at the level of
umbilicus.
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Venous samples were collected in vacationer tubes
after 12–14 h overnight fasting between 7:00 and 9:00
A.M and centrifuged within 30–45 min of collection.
Fasting plasma glucose (FPG) and 2-h post challenge
plasma glucose (2 h-PCPG) were measured by the en-
zymatic colorimetric method, using glucose oxidase; in-
ter- and intra-assay coefficients of variation at baseline
and follow-up phases were both less than 2.3 %. TC was
assayed, using the enzymatic colorimetric method with
cholesterol esterase and cholesterol oxidase. HDL-C was
measured after precipitation of the apolipoprotein B
(apo B)-containing lipoproteins with phosphotungistic
acid. TGs were assayed using glycerol phosphate oxi-
dase. Both intra- and inter-assay coefficients of varia-
tions for TC, HDL-C and TGs were less than 1.9, 3 and
2.1 %, respectively. Analyses were performed using related
kits (Pars Azmon Inc., Tehran, Iran) and a Selecta 2 auto-
analyzer (Vital Scientific, Spankeren, Netherlands) on the
day of blood sampling. All assays were done when quality
control met the acceptable criteria. To calculate LDL-C, a
modified Friedewald equation was used [21].
Definition of terms
Participants were classified as having type 2 diabetes if
they met at least one of the following criteria: FPG ≥
7 mmol/L, 2 h-PCPG ≥ 11.1 mmol/L or taking antidia-
betic medications. Moreover, prediabetes was defined as
having a 5.55 mmol/L ≤ FPG < 7 mmol/L and/or a
7.77 mmol/L ≤ 2 h-PCPG < 11.1 mmol/L, without using
glucose lowering drugs; those with FPG < 5.55 mmol/L
and 2 h-PCPG < 7.77 mmol/L were considered as nor-
mal glucose tolerant according to the definition of
American Diabetes Association [22]. Hypertension was
defined as systolic blood pressure (SBP) ≥ 140 mmHg or
diastolic blood pressure (DBP) ≥ 90 mmHg, or taking anti-
hypertensive medications. Prehypertension was defined as
SBP ≥ 120 mmHg and < 140 mmHg and DBP ≥ 80 mmHg
and < 90 mmHg and normotension as SBP < 120 mmHg
and DBP < 80 mmHg without any medication use [23]. A
current smoker was defined as a person who smokes ciga-
rettes daily or occasionally. Low physical activity was de-
fined as vigorous activity less than three times per week for
participants entered in first phase and as metabolic equiva-
lent task-minutes per week < 600 for those who entered in
the second phase [24]. Education status was categorized
into 3 groups: < 6 years, 6–12 years and ≥ 12 years. With
respect to the Kidney Disease Outcome Quality Initiative
guidelines, chronic kidney disease (CKD) was defined as ei-
ther kidney damage or estimated Glomerular Filtration
Rate (eGFR) < 60 mL/min/1.73 m2 for > 3 months [25].
Outcome measurement
Details of cardiovascular outcomes have been published
previously [19]. In the ongoing TLGS, all participants
are followed up for any medical event during the previ-
ous year by telephone. They are questioned by a trained
nurse regarding any medical conditions or whether a re-
lated event had occurred; a trained physician collected
complementary data during a home visit and/or a visit
to the respective hospital to collect data from medical
files; in case of mortality, data are collected from the hos-
pital or death certificate by an authorized local physician,
then evaluated by an outcome committee consisting of a
principal investigator, an internist, an endocrinologist, a
cardiologist, an epidemiologist and the physician who col-
lects the outcome data. Other experts are invited for
evaluation of non-communicable diseases, as needed. A
specific outcome for each event is assigned, based on the
International Statistical Classification of Diseases and Re-
lated Health Problems criteria, 10th Revision, and the
American Heart Association classification for cardiovascu-
lar events [19, 26]. In this study, first fatal and non-fatal
CHD event, stroke or cerebrovascular accidents were con-
sidered CVD events. By definition, CHD includes cases of
definite myocardial infarction diagnosed by electrocardio-
gram (ECG) and biomarkers, probable myocardial infarc-
tion (positive ECG findings plus cardiac symptoms or
signs and biomarkers showing negative or equivocal re-
sults), unstable angina pectoris (new cardiac symptoms or
changing symptom patterns and positive ECG findings
with normal biomarkers) and angiographic proven CHD.
CV mortality is specified as a composite measure of any
fatal CVD events, including fatal CHD and fatal stroke.
Statistical analysis
Mean and standard deviation (SD) values for continuous
and frequencies (%) for categorical variables of the base-
line characteristics were described and median (inter-
quartile range) for TGs and TGs/HDL-C as they had
skewed distribution.
Cox proportional hazard models with age as time scale
were used to evaluate associations of CVD events, CV
and non-CV mortality with one standard deviation (1-
SD) change in TC, LDL-C, HDL-C, non-HDL-C as well
as 1-SD increase in TC/HDL-C [27]. For TGs and TGs/
HDL-C, hazard ratios (HRs) were calculated for every 1-
SD increase in logarithm (ln)-transformed form of these
measures. The event time was defined as the time be-
tween entrance to the study and the endpoints. End-
points were considered as CVD event, CV and non-CV
mortality. Also censored data was defined as individuals
either lost to follow-up, having left residential area, having
non-CV mortality (for CV mortality endpoint) or contin-
ued up to March 2012, whichever occurred earlier.
Variables with p-values < 0.2 in univariate analysis were
included in the multivariate Cox model. Interaction be-
tween gender and lipid measures with CVD event, CV
and non-CV mortality was checked by log–likelihood
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ratio test, in multivariate analysis; since, there was no
significant interaction (all p-values > 0.1), analysis was
repeated in a pooled sample to reach acceptable statis-
tical power. Also, the effect of lipid measures on CVD
events was analysed in both genders. The interaction be-
tween prevalent CVD and lipid lowering drugs with lipid
markers was checked and since no significant interac-
tions were found (all p-values > 0.1), they were adjusted
in multivariate model.
In multivariate analysis, two models were applied;
model 1 included baseline levels of lipid profiles and
gender (female as reference); model 2, further adjusted
for potential covariates, included BMI, education status
(≥12 years as reference group), low physical activity,
smoking, blood pressure status (normotension as refer-
ence, prehypertension, hypertension), glucose tolerance
status (normal glucose tolerance as reference, prediabe-
tes, diabetes), lipid lowering drugs, and prevalent CVD
(for CV and non-CV mortality events). Additionally,
analyses were repeated for tertiles of all lipid measures
with the same approach. The annual CV and non-CV
mortality rate (per 1000 person-year) for each tertile of
lipid-measures was calculated by dividing the total num-
ber of incident events to the total person-years. The pro-
portionality of the multivariable Cox model was assessed
using Schoenfeld’s global test of residuals (p > 0.1).
Dietary intakes of nutrients were adjusted for total en-
ergy intakes, according to residuals method [28]. Potential
confounding effects of homeostatic model assessment-
insulin resistance (HOMA-IR) and dietary factors includ-
ing total fat, dietary cholesterol, total fiber, and Na/K ratio
were assessed for sensitivity analysis.
Statistical analyses were performed using STATA version
12.0 (Stata Corp LP, College Station, Texas). P values < 0.05
were considered statistically significant.
Results
The study sample consists of 5518 individuals (2532
men and 2986 women), with mean age (SD) of 55.46
(10.73) years in men and 53.18 (9.36) years in women.
Baseline characteristics in men and women are shown in
Table 1. There were significant difference in all variables
between men and women, except for TGs. Men were
older and had lower BMI, TC, LDL-C, HDL-C as well as
lower prevalence of prediabetes, diabetes, hypertension
and CKD; however, the levels of non-HDL-C, TC/HDL-
C, ln-TGs/HDL-C, prevalence of CVD, rate of current
smoking, prehypertension and low levels of physical ac-
tivity were higher in men.
We ascertained 789 incident CVD events among par-
ticipants free of CVD at baseline (n = 5054). The inci-
dence of CVD event for each 1000 person-year is shown
in Additional file 1: Table S1. In total population, the
multivariate adjusted HRs of CVD events for every 1-SD
increase in TC, LDL-C, non-HDL-C, ln-TGs, TC/HDL-
C and ln-TGs/HDL-C were associated with 26, 27, 22,
15, 18 and 14 %, respectively (Table 2); however, the cor-
responding change in HDL-C was associated with 7 %
decreased risk of CVD, which did not reach to statistical
significance (p = 0.07). Sex-stratified analysis did not
change the association between lipid parameters and
CVD events. Analysis using tertiles of lipid measures for
incident CVD showed the same results (Table 3).
During the study period, among the whole population,
549 mortality events (341 men and 208 women) com-
prising 279 CV mortality (183 men and 96 women) and
270 non-CV mortality (158 men and 112 women)
events, occurred. Different causes of non-CV mortality
included cancer (n = 85), sepsis (n = 46), accidents (n =
16), chronic obstructive pulmonary diseases (n = 2), and
unknown or miscellaneous causes (n = 121). The inci-
dence of CV and non-CV mortality for each 1000
person-year is shown in Additional file 1: Tables S2 and S3.
There were significant positive associations between
TC, LDL-C, non HDL-C and TC/HDL-C and CV mor-
tality events in sex-adjusted analysis (model 1); however
after adjustment with different covariates, these associa-
tions attenuated and reached to null (Table 4). Applying
lipid measures as categorical rather than continuous var-
iables, TC ≥ 6.14 mmol/L was associated with 52 % and
43 % increase in CV mortality risk in model 1 and 2, re-
spectively (Table 5). As shown in Table 6, in sex- and
multivariate adjusted analyses, there were negative sig-
nificant associations between all lipid measures except
HDL-C and non-CV mortality so that every 1-SD in-
crease in TC, LDL-C, non-HDL-C, ln-TGs, TC/HDL-C
and ln-TGs/HDL-C were associated with 24, 25, 27, 19,
23 and 17 % decrease in non-CV mortality. When lipid
measures were applied as categorical variables, the re-
sults generally remained unchanged (Table 7). In a sensi-
tivity analysis, excluding individuals who died within
3 years after initiation of the study as well as those with
BMI ≤ 18.5 kg/m2 (n = 164), the association between
lipid parameters and mortality events did not change
(Data not shown).
The association between lipid measures and CVD
events among 1548 participants, free of prevalent CVD
at baseline and available data on HOMA-IR, is shown in
Additional file 1: Tables S4 and S5. There was significant
association between lipid parameters and CVD events only
in sex-adjusted analysis; however, applying lipid measures
as categorical variables, significant risk for CVD events was
displayed in the second and third tertiles of TC, LDL-C
and non-HDL-C also third tertile of TC/HDL-C.
Discussion
This study determined relationship between different
lipid measures with CVD, CV and non-CV mortality
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during a long term follow-up in an Iranian adult popula-
tion. Our findings indicate a divergent associations of
TC, LDL-C, non-HDL-C, TC/HDL-C, ln-TGs and ln-
TGs/HDL-C with CVD vs non-CV mortality, with a
higher risk for the former and lower risk for the latter.
The absence of any interaction between gender and lipid
parameters indicated that being male vs female did not
affect the impact of lipid parameters on CVD, CV and
non-CV mortality events.
Lipid measures and cardiovascular events and CV mortality
Cholesterol is a major component of atherosclerosis and
CVD as an expression of atherosclerotic processes.
There are extensive epidemiological data demonstrating
that high blood cholesterol levels increase CVD and CV
mortality [6, 11, 15, 29]. In our study, TC ≥ 6.14 mmol/L
was associated with 85 and 43 % increase in CVD
and CV mortality, respectively. This finding is in agree-
ment with World Health Organization recommendations
Table 1 Baseline characteristics of participants in men, women and total population; Tehran Lipid and Glucose Study (TLGS) (2001–2012)
Total (N = 5518) Men (N = 2532) Women (N = 2986) p-value
Age, years 54.23(10.07) 55.46(10.73) 53.18(9.36) <0.001
BMI, kg/m2 27.86(4.59) 26.24(3.89) 29.24(4.69) <0.001
WC, cm 92.78(11.17) 91.26(10.5) 93.46(11.42) <0.001
SBP, mm Hg 126.78(21.16) 125.96(20.8) 127.47(21.45) 0.008
DBP, mm Hg 80.13(11.49) 79.35(11.88) 80.8(11.10) <0.001
FPG, mmol/L 5.89(2.22) 5.77(1.96) 5.99(2.41) <0.001
TC, mmol/L 5.73(1.22) 5.45(1.10) 5.98(1.26) <0.001
LDL-C, mmol/ L 3.97(1.02) 3.97(0.93) 4.12(1.07) <0.001
HDL-C, mmol/ L 1.08(0.28) 0.99(0.25) 1.15(0.29) <0.001
Non-HDL-C, mmol/ L 4.46(1.20) 4.46(1.10) 4.2(1.25) <0.001
TGs, mmol/ L 1.87(1.33) 1.84(1.35) 1.90(1.31) 0.06
TC/HDL-C 5.63(1.77) 5.82(1.83) 5.46(1.70) <0.001
TGs/HDL-C 1.81(1.67) 1.95(1.85) 1.70(1.50) <0.001
Current smoker, n (%) 862(15.6) 727(28.7) 135(4.5) <0.001
Low physical activity, n (%) 4401(79.8) 2082(82.2) 2319(77.7) <0.001
Education level, n (%) <0.001
≥ 12 years 490(8.9) 368(14.6) 122(4.1)
6-11 years 1939(35.2) 1065(42.1) 874(29.3)
< 6 years 3082(55.9) 1096(43.3) 1986(66.6)
Prevalent CVD, n (%) 464(8.4) 252(10.0) 212(7.1) <0.001
Prevalent CKD, n (%) 1617(29.3) 494(19.5) 1123(37.6) <0.001
Glucose tolerance, n (%) 0.003
Normal glucose tolerance 3022(57.3) 1442(59.5) 1580(55.4)
Prediabetes 1445(27.4) 647(26.7) 798(28.0)
Diabetes 806(15.3) 333(13.7) 473(16.6)
Blood pressure status, n (%) <0.001
Normotension 1714(31.1) 862(34.0) 852(28.5)
Prehypertension 1832(33.2) 862(34.0) 970(32.5)
Hypertension 1972(35.7) 808(31.9) 1164(39.0)
Hypertension drug, n (%) 769(13.9) 230(9.1) 539(18.1) <0.001
Lipid lowering drugs, n (%) 306(5.5) 83(3.3) 223(7.5) <0.001
Diabetes drug, n (%) 424(7.7) 152(6.0) 272(9.1) <0.001
Data are shown as mean ± SD for continuous variables (p value calculated with the t test), n (%) for categorical variables (p-value according to the chi-squared test)
or median (interquartile range) for TGs and TGs/HDL-C (p-value according to the Mann–Whitney U test)
BMI body mass index, WC waist circumference, SBP systolic blood pressure, DBP diastolic blood pressure, FPG fasting plasma glucose, TC total cholesterol, LDL-C
low density lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol, TGs triglycerides, CVD cardiovascular disease, CKD chronic kidney disease
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for CVD risk assessment in low and medium resource
countries [30].
In the current study, every 1-SD increment in non-
HDL-C and LDL-C was associated with 22 and 27 % in-
creased CVD risk, respectively, findings in line with the
results of a meta-analysis regarding markers of cardio-
vascular risk that demonstrated standardized relative risk
for every 1-SD increase in non-HDL-C and LDL-C was
34 and 25 % , respectively [3]. Meanwhile, non-HDL-
C ≥ 4.09 mmol/L was associated with 39 % increase in
risk of CVD and further 1 mmol/L increment duplicated
the risk. In a recent genetic study including data source
from TLGS, several variants with large effects on lipid
concentrations and their causal relationship with coron-
ary artery disease (CAD) have been discovered; among
them, the non-HDL cholesterol genetic risk score has
been associated most strongly with CAD [31].
In the present study, increase in serum TGs and TGs/
HDL-C was associated with increased CVD events, but
not CV mortality. We have previously shown that
among Iranian population aged ≥ 50 years, a 1-SD incre-
ment in ln-TGs is significantly associated with more
than 27 % increased risk for CHD [18]. A long-standing
association exists between elevated TG levels and CVD
[32–34]. Epidemiological and genetic evidence supporting
impact of raised TG remnant cholesterol or triglyceride-
rich lipoproteins (TRL) as an additional cause of CVD and
all-cause mortality. Nordestgaard et al., acknowledged that
TG concentrations of 2–10 mmol/L create an increased
risk of CVD [35]. Moreover, mendelian randomization
Table 2 Hazard ratios of lipid measures for predicting first cardiovascular disease events among participants without prevalent CVD
(n = 5054); Tehran Lipid and Glucose Study (TLGS) (2001–2012)a
Model 1 Model 2
SD (mmol/L) HR (95 % CI) p-value HR (95 % CI) p-value
Men
TC 1.10 1.34(1.22-1.47) <0.001 1.3(1.18-1.43) <0.001
LDL-C 0.93 1.37(1.25-1.51) <0.001 1.33(1.2-1.46) <0.001
HDL-C 0.25 0.88(0.79-0.98) 0.021 0.94(0.84-1.04) 0.24
Non-HDL-C 1.11 1.37(1.25-1.5) <0.001 1.32(1.20-1.45) <0.001
ln-TGs 0.57 1.20(1.09-1.3) <0.001 1.1(1.0-1.21) 0.05
TC/HDL-C 1.85 1.10(1.13-1.28) <0.001 1.17(1.09-1.25) <0.001
ln-TGs/HDL-C 0.7 1.2(1.1-1.31) <0.001 1.1(1.0-1.21) 0.056
Women
TC 1.24 1.30(1.18-1.43) <0.001 1.21(1.1-1.34) <0.001
LDL-C 1.05 1.30(1.19-1.43) <0.001 1.22(1.11-1.35) <0.001
HDL-C 0.29 0.87(0.78-0.98) 0.02 0.91(0.82-1.02) 0.11
Non-HDL-C 1.23 1.32(1.20-1.45) <0.001 1.23(1.12-1.36) <0.001
ln-TGs 0.51 1.42(1.27-1.58) <0.001 1.24(1.1-1.4) <0.001
TC/HDL-C 1.69 1.33(1.21-1.46) <0.001 1.26(1.13-1.4) <0.001
ln-TGs/HDL-C 0.65 1.38(1.23-1.54) <0.001 1.22(1.09-1.38) 0.001
Total
TC 1.21 1.33(1.24-1.42) <0.001 1.26(1.18-1.35) <0.001
LDL-C 1.01 1.34(1.26-1.43) <0.001 1.27(1.19-1.36) <0.001
HDL-C 0.28 0.88(0.81-0.95) 0.001 0.93(0.86-1.007) 0.07
Non-HDL-C 1.19 1.35(1.26-1.44) <0.001 1.22(1.14-1.30) <0.001
ln-TGs 0.53 1.28(1.20-1.37) <0.001 1.15(1.07-1.24) <0.001
TC/HDL-C 1.78 1.24(1.18-1.30) <0.001 1.18(1.12-1.25) <0.001
ln-TGs/HDL-C 0.67 1.27(1.18-1.36) <0.001 1.14(1.06-1.23) <0.001
Model 1: Lipid profile + gender (for total population); model 2 =model 1 + blood pressure status (i.e. normotension, prehypertension and hypertension status),
glucose tolerance status (normal glucose tolerance, prediabetes and diabetes), education status, low physical activity, current smoker, lipid lowering drugs and
body mass index
aHazard ratios (HR) indicate the increased risk for every 1-SD increase of each lipid parameter
CVD cardiovascular disease, SD standard deviation, TC total cholesterol, LDL-C low density lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol,
ln-TGs logarithm-transformed triglycerides, CI confidence interval
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that can contribute to the evidence or against the causal
effect of plasma lipids on atherosclerosis hypothesized
causality of TG in CAD risk [36]. Several new variants of
angiopoietin-like 4, a lipoprotein lipase inhibitor, leading
to decreased serum TG levels, have been associated with
protection from CVD [37, 38].
There was no significant association between HDL-C
and CVD and CV mortality in our study. Different types
of HDL-C particles based on their free cholesterol/
phospholipid ratio and availability of apolipoprotein A-1
(apo A-1), exhibit different biological effects including
reverse cholesterol transport resulting in different levels of
cardio-protection [39]. Jensen et al., report that dysfunc-
tional HDL-C containing apo lipoprotein CIII (apo CIII),
stimulates inflammatory and atherogenic responses in
cells involved in mortality and atherosclerosis [40]. The
level of apo CIII is affected by race/ethnicity [41]. Asians
have more dysfunctional apo CIII-containing HDL-C than
Western population [42], a condition that could predis-
pose them to higher mortality risk with increasing levels
of HDL-C. A recent study conducted on TLGS data re-
vealed increasing HDL-C as a CHD risk factor for pre-
menopausal women [43]. Based on the findings from the
Lipoprotein Investigators Collaborative study, some HDL-
C subclasses may be responsible for the inverse associ-
ation of HDL-C with CHD [44]. Moreover, a survey by
Rohatgi et al., in a population-based cohort, revealed that
although baseline HDL-C level was not associated with
CVD, cholesterol efflux capacity, as a novel biomarker of
reverse cholesterol transport, was inversely associated
with the incidence of CVD [45]. On the other hand, large
population-based studies have displayed that subjects who
Table 3 Hazard ratios for predicting first cardiovascular disease based on to lipid profile tertiles of participants without prevalent
CVD (n = 5054); Tehran Lipid and Glucose Study (TLGS) (2001–2012)
Model 1 Model 2
Tertiles of variables Tertiles of variables P for trend*
1 2 3 1 2 3
Men
TC, mmol/L Reference 1.28(1.02-1.6) 1.96(1.56-2.46) Reference 1.28(1.02-1.61) 1.84(1.46-2.32) <0.001
LDL-C, mmol/L Reference 1.36(1.08-1.71) 1.88(1.49-2.36) Reference 1.38(1.09-1.74) 1.76(1.39-2.23) <0.001
HDL-C, mmol/L Reference 0.90(0.72-1.12) 0.81(0.64-1.02) Reference 0.94(0.75-1.17) 0.92(0.72-1.31) 0.44
Non-HDL-C, mmol/L Reference 1.35 (1.07-1.7) 1.86 (1.48-2.33) Reference 1.35 (1.07-1.70) 1.72 (1.36-2.18) <0.001
TGs, mmol/L Reference 1.24(0.98-1.57) 1.55(1.24-1.95) Reference 1.1(0.87-1.4) 1.25(0.98-1.60) 0.07
TC/HDL-C Reference 1.35(1.05-1.73) 1.74(1.37-2.21) Reference 1.25(0.97-1.61) 1.54(1.2-1.98) 0.001
TGs/HDL-C Reference 1.32(1.03-1.68) 1.63(1.29-2.06) Reference 1.20(0.93-1.54) 1.34(1.04-1.72) 0.02
Women
TC, mmol/L Reference 1.72(1.18-2.52) 2.23(1.57-3.18) Reference 1.64(1.20-2.40) 1.98(1.39-2.83) <0.001
LDL-C, mmol/L Reference 1.89(1.32-2.72) 2.36(1.67-3.32) Reference 1.79(1.25-2.58) 2.09(1.48-2.96) <0.001
HDL-C, mmol/L Reference 1.14(0.84-1.54) 0.87(0.66-1.14) Reference 1.19(0.88-1.61) 0.95(0.72-1.26) 0.49
Non-HDL-C, mmol/L Reference 1.71 (1.19-2.45) 2.39 (1.7-3.36) Reference 1.57 (1.09-2.27) 2.09 (1.48-2.95) <0.001
TGs, mmol/L Reference 1.39(1.02-1.89) 2.09(1.57-2.79) Reference 1.17(0.85-1.60) 1.5(1.1-2.03) 0.006
TC/HDL-C Reference 1.56(1.17-2.07) 2.08(1.57-2.74) Reference 1.39(1.04-1.86) 1.78(1.34-2.36) <0.001
TGs/HDL-C Reference 1.45(1.1-1.91) 1.75(1.33-2.31) Reference 1.23(0.93-1.62) 1.33(1.0-1.77) 0.05
Total
TC, mmol/L Reference 1.39(1.15-1.68) 2.02(1.68-2.43) Reference 1.36(1.12-1.66) 1.85(1.53-2.23) <0.001
LDL-C, mmol/L Reference 1.5(1.23-1.81) 2.01(1.67-2.42) Reference 1.48(1.22-1.79) 1.84(1.52-2.22) <0.001
HDL-C, mmol/L Reference 0.97(0.82-1.16) 0.82(0.69-0.97) Reference 1.01(0.85-1.21) 0.92(0.77-1.09) 0.34
Non-HDL-C Reference 1.44(1.19-1.75) 2.03(1.69-2.44) Reference 1.39(1.15-1.70) 1.82(1.51-2.20) <0.001
TGs, mmol/L Reference 1.29(1.07-1.55) 1.77(1.48-2.11) Reference 1.12(0.92-1.35) 1.35(1.12-1.63) 0.001
TC/HDL-C Reference 1.44(1.19-1.73) 1.89(1.58-2.26) Reference 1.31(1.08-1.58) 1.63(1.35-1.96) <0.001
TGs/HDL-C Reference 1.37(1.15-1.65) 1.69(1.42-2.02) Reference 1.21(1.001-1.45) 1.33(1.11-1.61) 0.003
Model 1: lipid profile tertiles + gender (for total population); model 2 =model 1 + blood pressure status (i.e. normotension, prehypertension and hypertension
status), glucose tolerance status (normal glucose tolerance, prediabetes and diabetes), education status, low physical activity, current smoker, lipid lowering drugs
and body mass index
CVD cardiovascular disease, TC total cholesterol, LDL-C low density lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol, TGs triglycerides, CI
confidence interval. *P-values were calculated using age scale Cox proportional hazards regression models
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are carriers of scavenger receptor BI (the major receptor for
HDL-C) mutation have significantly increased levels of
plasma HDL-C but an increased risk of CHD (odds ratio =
1.79) [46]. To summarize, for evaluation of the effect of
HDL-C on CVD outcomes and mortality events, recent
studies emphasize the importance of HDL phenotypes ra-
ther than its measured concentration.
Lipid measures and non-cardiovascular mortality
In the present study, multivariate analysis showed that
every 1-SD increment in all lipid measures except HDL-
C was associated with 17–27 % decreased risk of non-
CV mortality. Several studies have demonstrated the
inverse association between lipid parameters and mortal-
ity in specific subpopulations including the elderly and
those with CKD [13, 47]; however, in the current study
the presence of CKD did not remain as a covariate even
in the univariate analysis (P > 0.6). In a population-based
study of individuals aged ≥ 50 years in Denmark, higher
lipoprotein levels (including TC and LDL-C) showed a
survival benefit compared with recommended low levels
[13]. In the Norwegian Counties Study, it was revealed
that the second and third quintiles of TGs (1.10 to
1.93 mmol/L) among men were significantly associated
with lower risk of all-cause mortality events [48]. Among
population of the present study, the inverse relationship
between lipid measures and non-CV mortality events
did not change after excluding participants with survival
< 3 years and those with BMI ≤ 18.5 kg/m2 at baseline.
The demonstrated inverse association between lipid pa-
rameters and non-CV mortality might be due to the re-
sidual effect of other conditions such as malnutrition,
inflammation and sarcopenia [49, 50] that could not be
assessed in our study. Furthermore, socioeconomic sta-
tus exposing the individuals to a wide range of risk fac-
tors for poor health would explain some of the
Table 5 Crude and multivariate adjusted hazard ratios of cardiovascular mortality based on lipid profile tertiles of total participants
(n = 5518); Tehran Lipid and Glucose Study (TLGS) (2001–2012)
Model 1 Model 2
Tertiles of variables Tertiles of variables
1 2 3 1 2 3 P for trend*
TC, mmol/L Reference 1.27(0.93-1.73) 1.52(1.12-2.08) Reference 1.17(0.84-1.62) 1.43(1.04-1.98) 0.027
LDL-C, mmol/L Reference 1.27(0.93-1.73) 1.42(1.05-1.93) Reference 1.19(0.86-1.64) 1.29(0.94-1.78) 0.12
HDL-C, mmol/L Reference 0.89(0.66-1.20) 0.89(0.67-1.19) Reference 0.98(0.72-1.34) 1.06(0.78-1.42) 0.71
Non-HDL-C Reference 1.20(0.89-1.63) 1.17(0.87-1.58) Reference 1.17 (0.85-1.61) 1.24 (0.9-1.71) 0.19
TGs, mmol/L Reference 0.94(0.7-1.26) 1.14(0.86-1.52) Reference 0.83(0.61-1.13) 0.95(0.69-1.3) 0.77
TC/HDL-C Reference 0.96(0.71-1.30) 1.21(0.91-1.61) Reference 0.93(0.68-1.27) 1.0(0.74-1.36) 0.95
TGs/HDL-C Reference 1.23(0.93-1.64) 1.1(0.82-1.5) Reference 0.96(0.71-1.30) 0.85(0.62-1.18) 0.33
Model 1: lipid profile tertiles + gender; model 2 =model 1 + blood pressure status (i.e. normotension, prehypertension and hypertension status), glucose tolerance
status (normal glucose tolerance, prediabetes and diabetes), education status, low physical activity, current smoker, lipid lowering drugs, body mass index and
prevalent cardiovascular disease
TC total cholesterol, LDL-C low density lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol, TGs triglycerides, CI confidence interval
*P-values were calculated using age scale Cox proportional hazards regression models
Table 4 Hazard ratios of lipid measures for predicting cardiovascular mortality among total participants (n = 5518); Tehran Lipid and
Glucose Study (TLGS) (2001–2012)a
Model 1 Model 2
SD (mmol/L) HR (95 % CI) p-value HR (95 % CI) p-value
TC 1.22 1.16(1.03-1.31) 0.02 1.08(0.96-1.21) 0.22
LDL-C 1.01 1.16(0.4-0.67) 0.01 1.08(0.96-1.21) 0.19
HDL-C 0.28 0.96(0.85-1.10) 0.6 1.02(0.9-1.15) 0.77
Non-HDL-C 1.20 1.16(1.03-1.31) 0.01 1.02(0.91-1.15) 0.67
ln-TGs 0.32 1.10(0.98-1.24) 0.11 0.97(0.85-1.10) 0.61
TC/ HDL-C 1.77 1.15(1.03-1.28) 0.01 1.06(0.95-1.20) 0.29
ln-TGs/ HDL-C 0.76 1.10(0.97-1.24) 0.13 0.97(0.85-1.10) 0.61
Model 1: lipid profile + gender; model 2 =model 1 + blood pressure status (i.e. normotension, prehypertension and hypertension status), glucose tolerance status
(normal glucose tolerance, prediabetes and diabetes), education status, low physical activity, current smoker, lipid lowering drugs, body mass index and prevalent
cardiovascular disease
aHazard ratios (HR) indicate the increased risk for a 1-SD increase of each lipid parameter
SD standard deviation, TC total cholesterol, LDL-C low density lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol, ln-TGs logarithm-transformed
triglycerides, CI confidence interval
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aforementioned inverse relationship for non-CV mortal-
ity [51, 52].
Limitations and strengths
There are several limitations that should be addressed.
First, we measured lipid parameters only once at base-
line; thus the potential bias resulting from regression di-
lution could not be ignored. The underestimation of the
impact of lipids increased with time interval between
baseline and follow-up measurements for TC and TGs,
has previously been reported in TLGS cohort [53]. Sec-
ond, we applied modified Friedwald formula to calculate
the level of LDL-C rather than its direct measurement.
The collected data are remarkably consistent that LDL
particle (LDL-P) number is a better predictor of CV risk
compared with the standard measurement of LDL-C
concentration; however, these important but costly
atherogenic lipid particles were not measured in this
large population-based study. On the other hand, still,
we need standardization for LDL-P measurements [54].
Third, apo A-1, apo B and lipoprotein(a) (Lp[a]) were
not measured in the current study; however, Ingelsson
et al. have shown that overall performance of apo B/apo
A-1 for prediction of CHD is comparable with that of
traditional lipid ratios and results in no incremental util-
ity over TC/HDL-C [55]. Furthermore, a recent meta-
analysis including 37 prospective cohorts demonstrated
that information on non-HDL-C, apo B, apo A-I and
Lp(a) did not improve CVD prediction provided by sim-
ple measurements of TC and HDL-C [56]. Although the
Emerging Risk Factors Collaboration displayed continu-
ous associations of Lp(a) concentration with risk of
CHD, they claimed that there is significant variability in
measured Lp(a) concentration [57]. Forth, we did not
have data regarding inflammatory parameters including
C-reactive protein (CRP) and fibrinogen. Yeboah et al.,
Table 7 Crude and multivariate adjusted hazard ratios of non-cardiovascular mortality based on lipid profile tertiles of total participants
(n = 5518); Tehran Lipid and Glucose Study (TLGS) (2001–2012)
Model 1 Model 2
Tertiles of variables Tertiles of variables
1 2 3 1 2 3 P for trend*
TC, mmol/L Reference 0.73(0.55-0.98) (0.61-0.45-0.83) Reference 0.75(0.55-1.01) 0.57(0.42-0.79) 0.001
LDL-C, mmol/L Reference 0.62(0.46-0.83) 0.61(0.45-0.82) Reference 0.64(0.47-0.87) 0.57(0.42-0.77) <0.001
HDL-C, mmol/L Reference 0.86(0.63-1.19) 1.01(0.75-1.34) Reference 0.97(0.7-1.34) 1.07(0.79-1.45) 0.62
Non-HDL-C Reference 0.61(0.45-0.82) 0.63(0.47-0.84) Reference 0.62(0.46-0.84) 0.58(0.43-0.79) <0.001
TGs, mmol/L Reference 0.87(0.66-1.15) 0.71(0.52-0.96) Reference 0.8(0.60-1.08) 0.59(0.42-0.82) 0.002
TC/HDL-C Reference 0.78(0.58-1.03) 0.66(0.49-0.90) Reference 0.77(0.58-1.03) 0.6(0.44-0.83) 0.002
TGs/HDL-C Reference 0.91(0.69-1.21) 0.79(0.58-1.06) Reference 0.82(0.61-1.10) 0.65(0.47-0.91) 0.01
Model 1: lipid profile tertiles + gender; model 2 =model 1 + blood pressure status (i.e. normotension, prehypertension and hypertension status), glucose tolerance
status (normal glucose tolerance, prediabetes and diabetes), education status, low physical activity, current smoker, lipid lowering drugs, body mass index and
prevalent cardiovascular disease
TC total cholesterol, LDL-C low density lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol, TGs triglycerides, CI confidence interval
*P-values were calculated using age scale Cox proportional hazards regression models
Table 6 Hazard ratios of lipid measures for predicting non-cardiovascular mortality among total participants (n = 5518); Tehran Lipid
and Glucose Study (TLGS) (2001–2012)a
Model 1 Model 2
SD (mmol/L) HR (95 % CI) p-value HR (95 % CI) p-value
TC 1.22 0.8(0.70-0.92) 0.001 0.76(0.66-0.87) <0.001
LDL-C 1.01 0.79(0.69-0.90) <0.001 0.75(0.66-0.86) <0.001
HDL-C 0.28 1.08(0.95-1.22) 0.24 1.07(0.94-1.21) 0.32
Non-HDL-C 1.20 0.79(0.69-0.90) <0.001 0.73(0.64-0.84) <0.001
ln-TGs 0.32 0.89(0.78-1.0) 0.06 0.81(0.7-0.93) 0.002
TC/HDL-C 1.77 0.81(0.71-0.94) 0.004 0.77(0.67-0.89) 0.001
ln-TGs/HDL-C 0.76 0.89(0.79-1.01) 0.076 0.83(0.72-0.95) 0.006
Model 1: lipid profile + gender; model 2 =model 1 + blood pressure status (i.e. normotension, prehypertension and hypertension status), glucose tolerance status
(normal glucose tolerance, prediabetes and diabetes), education status, low physical activity, current smoker, lipid lowering drugs, body mass index and prevalent
cardiovascular disease
aHazard ratios indicate the increased risk for a 1-SD increase of each lipid parameter
SD standard deviation, TC total cholesterol, LDL-C low density lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol, ln-TGs logarithm-transformed
triglycerides, CI confidence interval
Ghasemzadeh et al. Nutrition & Metabolism  (2016) 13:43 Page 9 of 12
have reported improvement in the Framingham Risk
Score for prediction of CHD within intermediate-risk
participants using additional risk markers; nevertheless,
the net reclassification improvement for incident CHD
with high-sensitivity CRP was less than coronary artery
calcium, brachial flow-mediated dilation, ankle-brachial
index, carotid intima-media thickness and family history
[58]. On the other hand, during a short term follow-up
among Tehranian adult population, we have shown that
measurement of CRP has no added value for prediction
of CVD, over and above traditional risk factors [59].
Fifth, no information about nutrition transition of our
country was available in this period; an issue that might
affect the impact of lipid measures on mortality out-
comes. Sixth, the statistical power of our study to detect
a HR of 1.08 of TC (35 %) and LDL-C (25 %) for CV
mortality was low. Lastly, this study was performed in a
large sample of urban Tehranian population; hence it is
not possible to extrapolate our findings to the other
parts of country or Middle-Eastern region.
The strength of our prospective study lies in a reason-
able sample size, length of follow-up and direct meas-
urement of the different variables and outcomes rather
than self-reported data.; moreover, to the best, it was the
first long term prospective and population-based study
which investigated the association between different lipid
measures and CV vs non-CV mortality.
Conclusions
Findings of the present study indicate divergent associa-
tions between TC, LDL-C, non-HDL-C, TC/HDL-C, ln-
TGs and ln TGs/HDL-C and CVD vs non-CV mortality,
with a higher risk for the former and lower risk for the
latter, during a long term population-based study.
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